Our results, along the same line as others, suggest that MLASA may be only one of the clinical presentations of YARS2 pathogenic variants, and that some other syndromic causes of unknown origin or with incompletely described molecular pathogenic routes of sideroblastic anemia could also be associated to pathogenic variants in this gene [12]. This evidence concerns the gene YARS2 and sideroblastic anemia.